Leukemia drug shows promise in french compassionate use study
NCT ID NCT03751072
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how well blinatumomab works and how safe it is in 92 adults with B-cell acute lymphoblastic leukemia that had come back or was not responding to treatment. Patients received the drug through a French compassionate use program. Researchers measured survival, response rates, and side effects to better understand the drug's real-world impact.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab (a drug that helps immune cells attack leukemia cells)
- What this could lead to
- If results are positive, this could support wider use of blinatumomab for hard-to-treat leukemia patients who have few options.
- What could go wrong
- This is a retrospective review of a compassionate use program, not a controlled trial. Results may not be as strong as in formal studies, and side effects can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA WITH FAILED REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CABANNES-HAMY Aurélie
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- Engineered immune cells take on stubborn leukemia
- New CAR-T therapy aims to tackle tough blood cancers
- Donor immune cells take on tough leukemia in early trial
- Can immune booster cells revive failing CAR-T therapy in leukemia?
- Immunotherapy Follow-Up study launched for young cancer patients